美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Braveheart Bio

26.64

-0.6100-2.24%

盤後：26.640.00000.00%19:30 EDT

成交量：28.36萬

成交額：776.76萬

市值：23.99億

市盈率：-1.81

高：28.74

開：28.12

低：26.54

收：27.25

52周最高：32.00

52周最低：24.31

股本：9,003.90萬

流通股本：2,583.17萬

量比：0.78

換手率：1.10%

股息：- -

股息率：- -

每股收益(TTM):-14.6845

每股收益(LYR):-17.2003

淨資產收益率：--

總資產收益率：--

市淨率：-25.01

市盈率(LYR):-1.55

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Braveheart Bio

交易所：

NASDAQ

成立時間：

2024

員工人數：

49

公司地址：

One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States

官網：

http://www.braveheart.bio

郵編：

94129

電話：

傳真：

- -

簡介：

Braveheart Bio, Inc.於2024年5月13日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物製藥公司，專註於為肥厚型心肌病和其他嚴重心血管疾病患者開發療法。其主導候選產品BHB-1893是一種下一代口服小分子心肌肌球蛋白抑製劑，由江蘇恆瑞醫藥有限公司獲得全球授權，不包括大中華區，並已在恆瑞主要在中國和澳大利亞進行的臨床試驗中進行評估。

董事

名稱

職位

Christopher Viehbacher

Chairman of the Board and Director

Travis Murdoch

Chief Executive Officer, President and Director

David C. Lubner

Director

David Malek

Director

Erez Chimovits

Director

Jason Coloma

Director

Jasper Bos

Director

Tim Lohoff

Director

Vineeta Agarwala

Director

股東

名稱

職位

Travis Murdoch

Chief Executive Officer, President and Director

J. Paul Rickey

Chief Financial Officer

Emil deGoma

Chief Medical Officer

Marc Evanchik

Chief Scientific Officer

Michele Anderson

Chief Development Officer

Tyler Chavez

Chief Business Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BRVE/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":26.64,"timestamp":1789156800000,"preClose":27.25,"halted":0,"volume":283591,"hourTrading":{"tag":"盘后","latestPrice":26.64,"preClose":26.64,"latestTime":"19:30 EDT","volume":3375,"amount":89905.66,"timestamp":1789169407648,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02238532110091741,"floatShares":25831738,"shares":90039000,"eps":-14.684527,"marketStatus":"休市中","change":-0.61,"latestTime":"09-11 16:00:00 EDT","open":28.12,"high":28.74,"low":26.54,"amount":7767601.163013999,"amplitude":0.080734,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-14.684527,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":27.25,"postHourTrading":{"tag":"盘后","latestPrice":26.64,"preClose":26.64,"latestTime":"19:30 EDT","volume":3375,"amount":89905.66,"timestamp":1789169407648,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7839558186905717},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":25831738,"roa":"--","roe":"--","lyrEps":-17.200311,"volumeRatio":0.7839558186905717,"shares":90039000,"dividePrice":0,"high":28.74,"amplitude":0.080734,"preClose":27.25,"low":26.54,"week52Low":24.305,"pbRate":"-25.01","week52High":32,"institutionHeld":0,"latestPrice":26.64,"eps":-14.684527,"divideRate":0,"volume":283591,"delay":0,"ttmEps":-14.684527,"open":28.12,"prevYearClose":18,"prevWeekClose":26.74,"prevMonthClose":25.5,"prevQuarterClose":18,"fiveDayClose":26.27,"twentyDayClose":25.97,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-09-11","current":-1.814154,"percent":0.923077,"low":-23.993466,"twenty":-22.185958,"median":-21.618113,"eighty":-20.469626,"high":-12.297967,"avg":-20.979317,"sd":2.525661,"marketCap":1748603206},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250},{"date":"2026-09-04","current":-21.010278,"twenty":-22.169963,"median":-21.930028,"eighty":-20.827928,"marketCap":1685717659},{"date":"2026-09-11","current":-18.437402,"twenty":-22.185958,"median":-21.618113,"eighty":-20.469626,"marketCap":1748603206}],"updateTime":1789319562659},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1959705903,"yearFounded":2024,"employeeNum":49,"address":"One Letterman Drive,Building A,Suite A4-300,San Francisco,California,United States","zipCode":"94129","officePhone":"415 707 6312","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.braveheart.bio","stockEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0187},{"period":"3month","weight":0.48},{"period":"ytd","weight":0.48}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Braveheart Bio, Inc.於2024年5月13日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物製藥公司，專註於為肥厚型心肌病和其他嚴重心血管疾病患者開發療法。其主導候選產品BHB-1893是一種下一代口服小分子心肌肌球蛋白抑製劑，由江蘇恆瑞醫藥有限公司獲得全球授權，不包括大中華區，並已在恆瑞主要在中國和澳大利亞進行的臨床試驗中進行評估。","exchange":"NASDAQ","name":"Braveheart Bio","nameEN":"Braveheart Bio"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":{"directors":[{"name":"Christopher Viehbacher","position":"Chairman of the Board and Director"},{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"David C. Lubner","position":"Director"},{"name":"David Malek","position":"Director"},{"name":"Erez Chimovits","position":"Director"},{"name":"Jason Coloma","position":"Director"},{"name":"Jasper Bos","position":"Director"},{"name":"Tim Lohoff","position":"Director"},{"name":"Vineeta Agarwala","position":"Director"}],"executives":[{"name":"Travis Murdoch","position":"Chief Executive Officer, President and Director"},{"name":"J. Paul Rickey","position":"Chief Financial Officer"},{"name":"Emil deGoma","position":"Chief Medical Officer"},{"name":"Marc Evanchik","position":"Chief Scientific Officer"},{"name":"Michele Anderson","position":"Chief Development Officer"},{"name":"Tyler Chavez","position":"Chief Business Officer"}]}}}